FitLife Brands, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
FitLife Brands, Inc. develops and sells nutritional supplements and wellness products under the NDS, iSatori, MRC and MusclePharm brands. Products are sold through GNC, approximately 16,000 retail locations, wholesale customers and online channels. The company operates as one reportable segment.
This filing covers the unaudited three months ended March 31, 2024, compared with the three months ended March 31, 2023. Amounts are in thousands, except per-share data.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $16,549 | $10,738 | 54% |
| Gross profit | $7,287 | $4,408 | 65% |
| Gross margin | 44.0% | 41.1% | +290 bps |
| Operating income | $3,381 | $673 | 402% |
| Operating margin | 20.4% | 6.3% | +14.1 pts |
| Net income | $2,160 | $156 | 1,258% |
| Net margin | 13.1% | 1.5% | +11.6 pts |
| Diluted EPS | $0.43 | $0.03 | Increase |
| Adjusted EBITDA | $3,648 | $2,246 | 62% |
| Cash flow from operations | $5,036 | $232 | Increase |
Online revenue represented approximately 65% of revenue, compared with 47% in the prior-year quarter; wholesale revenue represented approximately 35%, compared with 53%. Approximately 96% of Q1 2024 sales were to U.S. customers.
Balance Sheet, Debt and Liquidity
- Cash and cash equivalents were $2,540 at March 31, 2024, and restricted cash was $750, for total cash and restricted cash of $3,290.
- Working capital was $3,164, down from $4,356 at December 31, 2023.
- Accounts receivable were $2,269 and inventory was $8,869.
- Total term-loan borrowings were $16,500, consisting of $7,500 under Term Loan A and $9,000 under Term Loan B. The carrying amount, net of debt issuance costs, was $16,394.
- The company had no borrowings under its $3.5 million revolving line of credit, which was extended to December 15, 2024.
- The company paid $3,625 of term-loan principal during the quarter, including a voluntary $2,500 paydown and scheduled amortization of $1,125.
- Management stated that operating cash flow, existing cash and available revolver capacity are expected to provide liquidity for the next twelve months, while noting that no assurance can be given.
Material Changes Versus the Prior Comparable Period
- Revenue growth primarily reflected a full quarter of MRC revenue and the contribution from MusclePharm, acquired in October 2023. MRC generated $7,493 of Q1 2024 revenue and MusclePharm generated approximately $2.1 million.
- Legacy FitLife revenue declined 14% to $6,961, including a 21% decline in wholesale revenue partially offset by a 3% increase in online revenue.
- Gross margin improved mainly because of MRC sales mix and the absence of the $110 MRC inventory fair-value step-up amortization recorded in Q1 2023.
- SG&A increased 59% to $3,736, primarily because of the full-quarter impact of MRC operating expenses.
- Merger and acquisition-related expense fell 90% to $134 from $1,372, as the prior-year period included significant MRC transaction costs.
- Interest expense increased to $414 from $98 because of acquisition-related debt and higher interest rates.
- Investing cash use fell to $10 from $17,099 because the prior-year period included the cash acquisition of MRC.
- Cash flow from operations increased substantially, supported by net income and changes in receivables, inventory, sales-tax receivables and payables.
Outlook, Risks and Unusual Items
Management expects online revenue to continue increasing relative to prior comparable periods, citing its focus on higher-margin online sales and the MRC and MusclePharm acquisitions. The filing does not provide quantitative revenue or earnings guidance.
- The term loans bear interest at one-month SOFR plus 2.75%, exposing the company to variable-rate risk. The company also has foreign-currency exposure, principally through its Canadian operations.
- The credit agreement requires a minimum fixed-charge coverage ratio of 1.25 to 1.00 and a maximum funded-debt-to-EBITDA ratio of 2.50 to 1.00. The company reported compliance with all covenants at March 31, 2024.
- If specified cash-flow leverage conditions are not met after June 30, 2025 while term-loan balances remain outstanding, the company may be required to prepay 50% of excess cash flow.
- GNC represented 25% of Q1 2024 revenue, creating customer concentration risk. One vendor represented 62% of accounts payable at March 31, 2024, and two vendors represented 69% of inventory-related purchases during the quarter.
- Goodwill and indefinite-lived brand assets are subject to impairment testing. Management reported no impairment indicators at March 31, 2024 and expects its next annual analysis in December 2024.
- The company reported no material pending litigation, no senior-security defaults and no material changes to the risk factors disclosed in its 2023 Form 10-K.
- Stock-based compensation was $102, and diluted weighted-average shares increased to 5,030 from 4,935 due to the dilutive effect of options and warrants.
Investor Verification Checklist
- Verify whether the revenue contribution and profitability of MRC and MusclePharm are sustainable and whether legacy FitLife revenue stabilizes.
- Track online-channel growth, gross-margin performance and the effect of product and customer mix.
- Review term-loan amortization, SOFR sensitivity, covenant compliance and revolver availability through the December 2024 maturity date.
- Assess customer and supplier concentration, particularly GNC and the company’s largest vendor.
- Monitor goodwill and brand-asset impairment indicators, including changes in the company’s stock price and operating outlook.
- Reconcile adjusted EBITDA to GAAP net income and evaluate the recurring nature of excluded acquisition, stock-compensation and other items.